Research progress on the regulation of JAK/STAT3 signaling pathway by traditional Chinese medicine in the treatment of ovarian cancer

Article Sidebar

PDF
Published: Dec 30, 2023
Keywords:
ovarian cancer JAK/STAT3 traditional Chinese medicine research progress

Main Article Content

Zhang Jie
Central Laboratory of Science and Technology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China
Qi Cong
Gynecology and Obstetrics Department, Shuguang Hospital Shanghai University of Traditional Chinese Medicine，China
Dai Weiwei
Central Laboratory of Science and Technology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China
Wu Hongjin
Central Laboratory of Science and Technology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China
Wang Libo
Central Laboratory of Science and Technology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China
Wang Chenglong
Central Laboratory of Science and Technology Department, Longhua Hospital Shanghai University of Traditional Chinese Medicine, China

Abstract

JAK-STAT (Janus kinases & signal transducer and activator of transcription proteins) is closely related to various physiological and pathological processes of ovarian cancer. Traditional Chinese medicine has become a major focus in tumor treatment due to its advantages of preventive treatment and multiple components, targets, and pathways. This article provides a comprehensive review on the relationship between the JAK/STAT3 signaling pathway and ovarian cancer, as well as the regulatory role of traditional Chinese medicine, in order to provide new ideas for clinical research and drug development of ovarian cancer.

Article Details

Issue
Vol. 2 No. 2 (2023): July-December 2023
Section
Review Article

References

Gynecological Oncology Professional Committee of China Anti-Cancer Association. Guidelines for the diagnosis and treatment of ovarian malignant tumors (2021 edition). China Oncology. 2021;31(6):490-500. (in Chinese)

Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.

Wu YS, Xu SL, Cheng SS, Yang JN, Wang Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023;16(1):1-15.

Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-21.

Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503-14.

Zhao JZ, Jiang XX, Li HW, Qin ZH, Chen YH, Liu R, et al. Research progress on JAK-STAT signaling pathway and regulation of macrophage inflammation. Carcinogenesis, Teratogenesis & Mutagenesis. 2020;32(5):402-8. (in Chinese)

Xue X, Liu HM, Shao DB, Tang WJ, Nie SN. Research progress of regulating mechanism on JAK/STAT signaling pathway. Progress in Modern Biomedicine. 2015;15(11):2161-5. (in Chinese)

Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000;79(1):67-73.

Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer. 2009;125(9):2198-204.

Jin PF, Liu YJ, Wang RJ. STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance. Biosci Rep. 2018;38(4): BSR20180547.

Chen HZ, Ye DF, Xie X, Chen BY, Lu WG. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol. 2004;94(3):630-5.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538-48.

Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22(10):1517-27.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8.

Chong KY, Kang M, Garofalo F, Ueno D, Liang HM, Cady S, et al. Inhibition of heat shock protein 90 suppresses TWIST1 transcription. Mol Pharmacol. 2019;96(2):168-79.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 2017;36(2):168-81.

Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 2017;77(8):1955-67.

Ning YX, Cui YH, Li X, Cao XC, Chen A, Xu C, et al. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8/STAT3 signaling. Biomed Pharmacother. 2018;103:262-71.

Giordano M, Decio A, Battistini C, Baronio M, Bianchi F, Villa A, et al. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling. J Exp Clin Cancer Res. 2021;40(1):319.

Ruan ZY, Yang XY, Cheng WW. OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells. Cancer Manag Res. 2018;11:389-99.

Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685-93.

Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019;11(12):2002.

Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013;12(6):489-98.

Wang XP, Zhao XB, Wang K, Wu L, Duan T. Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Sci. 2013;104(4):516-23.

Yang S, Shen Y, Han FJ. Therapeutic effect and research progress of traditional Chinese medicinal on ovarian cancer. Liaoning Journal of Traditional Chinese Medicine. 2021;48(10):202-7. (in Chinese)

Li EZ, Guo YP, Wang GL, Chen FJ, Li QW. Effect of resveratrol on restoring spermatogenesis in experimental cryptorchid mice and analysis of related differentially expressed proteins. Cell Biol Int. 2015;39(6):733-40.

Li GL, Liu J, Xie J. Effects of resveratrol on proliferation, apoptosis, migration and invasion of ovarian cancer SKOV-3 cells by regulating IL-6/JAK2/STAT3 signaling pathway. Acta Universitatis Medicinalis Anhui. 2020;55(5):706-11. (in Chinese)

Zhong YY. Study on the mechanism of triptolide regulating JAK2/STAT3/Mcl-1 autophagic pathway against cisplatin-resistant epithelial ovarian cancer. Nanchang: Nanchang University; 2021. (in Chinese)

Riaz A, Rasul A, Kanwal N, Hussain G, Shah MA, Sarfraz I, et al. Germacrone: a potent secondary metabolite with therapeutic potential in metabolic diseases, cancer and viral infections. Curr Drug Metab. 2020;21(14):1079-90.

He CY, Ren QC. Effect of JAK2/STAT3 signaling pathway regulated by Germacrone on cell viability of ovarian cancer SKOV3. Academic Journal of Chinese PLA Medical School. 2021;42(8):886-72. (in Chinese)

Liang H, Zheng T, Lan H, Wang J, Li MH, Song DP. Research progress on anti-tumor mechanism of raddeanin A. Drugs & Clinic. 2022;37(7):1676-80. (in Chinese)

Fan SZ, Zhao SJ, Qin QH, Gao X, Wang BJ, Li HY. Experimental study of the inhibitory effect of raddeanin A on proliferation and invasion of SKOV3 cells by JAK/STAT3 pathways. Clinical Research. 2021;29(10):1-5. (in Chinese)

Yang XY, Xue ZY, Fang YY, Liu XH, Yang YF, Shi GG, et al. Structure-immunomodulatory activity relationships of hedysarum polysaccharides extracted by a method involving a complex enzyme combined with ultrasonication. Food Funct. 2019,10(2):1146-58.

Jiang HJ, Zhong GQ, Zhang Y. Hedysarum polysaccharide mediates the STAT3 pathway to inhibit the immune escape of tumor cells in ovarian cancer mice. Immunological Journal. 2023,39(3):233-9. (in Chinese)